LesinskiLab
@lesinskilab.bsky.social
460 followers
310 following
25 posts
The Lesinski Laboratory is focused on understanding the interactions between the immune system and cancer. opinions are my own. #immunotherapy #GICancer
Posts
Media
Videos
Starter Packs
LesinskiLab
@lesinskilab.bsky.social
· Jul 3
Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed
These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...
pubmed.ncbi.nlm.nih.gov
LesinskiLab
@lesinskilab.bsky.social
· Apr 28
Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking
Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...
www.biorxiv.org
Reposted by LesinskiLab
LesinskiLab
@lesinskilab.bsky.social
· Apr 19
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Our understanding of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) primarily stems from murine models or primary patient tumors. While metastatic tumors have generally less ...
www.biorxiv.org
LesinskiLab
@lesinskilab.bsky.social
· Mar 14
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial
We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced co...
www.tandfonline.com
LesinskiLab
@lesinskilab.bsky.social
· Feb 13
Reposted by LesinskiLab
Reposted by LesinskiLab
LesinskiLab
@lesinskilab.bsky.social
· Dec 26
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
Nagaraju et al. have identified that paricalcitol (P) plus hydroxychloroquine (H) potentiates the efficacy of gemcitabine (G) in PDAC. GPH treatment induces ER stress and autophagy with M1 polarization and T cell activation. These findings in PDAC patient-derived data highlight the potential translational impact of GPH therapy in improving clinical outcomes.
www.cell.com
Reposted by LesinskiLab